ArticleExperimental and therapeutic medicine2025
Synchronous thyroid medullary cancer and thyroid hemiagenesis: A case report.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unveiling the rare coexistence: thyroid hemiagenesis and thyroid cancer - case series and comprehensive review.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid hemiagenesis (TH) is a rare, congenital malformation defined as the absence of one thyroid lobe with or without an isthmus. By contrast, medullary thyroid cancer (MTC) is a rare thyroid malignancy, arises from parafollicular C cells. In the current study, a 33-year-old man presented with a small mass on the left side of the neck. Ultrasonography indicated a hyperechoic nodule in the left lobe of the thyroid gland and the right thyroid lobe could not be visualized. The patient underwent fine-needle aspiration cytology and MTC was suspected. The patient underwent total thyroidectomy, bilateral central lymph node dissection and left cervical compartment dissection. L-thyroxine (100 µg/per day) commenced immediately following thyroidectomy. During follow-up (monitored every 3 months), the patient remained healthy with no evidence of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.